immuno-oncology in nsclc: cost versus benefit
Published 5 years ago • 79 plays • Length 3:20Download video MP4
Download video MP3
Similar videos
-
5:10
immuno-oncology combination therapy in nsclc
-
7:16
immuno-oncology combination therapy: which patients with nsclc?
-
5:52
future directions in nsclc immuno-oncology research
-
3:46
emerging immunotherapies and combinations for nsclc
-
3:36
measuring response with immuno-oncology agents in nsclc
-
5:43
duration of upfront immunotherapy for nsclc
-
1:18
dr. natale on the evolution of immunotherapy in nsclc
-
2:10
dr. langer on the benefit of durvalumab in stage iii nsclc
-
7:00
novel immunotherapy combinations in nsclc
-
1:50
dr. goldberg on immune/targeted therapy combos in oncogene-driven lung cancer
-
1:25
dr. wolf on updated findings with capmatinib in metex14-mutant nsclc
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
0:52
dr. stinchcombe on the benefit of alectinib in alk nsclc
-
2:04
dr. kelly on challenges with starting immunotherapy in lung cancer
-
37:31
update on immuno-oncology biomarkers
-
1:16
dr. levy on treatments for oncogenic-driven nsclc
-
5:18
nsclc management: second-line options
-
1:02:36
practice changes for use of immunotherapy in nsclc
-
5:04
upfront immunotherapy chemotherapy for nsclc